Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

New Drugs VI

No authors listed
Tom Perry
, editors.
In: Therapeutics Letter. Vancouver (BC): Therapeutics Initiative; 1994. Letter 36.
2000 Aug.
Free Books & Documents
Review

New Drugs VI

No authors listed.
Free Books & Documents

Excerpt

Therapeutics Letter 36 examines benefits and harms of new drugs rosiglitazone, tolterodine, bupropion, and doxazosin. Conclusions: In patients with type 2 diabetes rosiglitazone improves some surrogate markers and worsens others. Long-term trials are required to know whether this class of drugs reduces morbidity and mortality outcomes. Tolterodine and oxybutynin have similar but limited efficacy in patients with overactive bladder symptoms. Dry mouth is a common side effect and occurs more frequently with oxybutynin (78%) than with tolterodine (40%). Bupropion has antidepressant and smoking cessation effects through a unique mechanism of action. The adverse effect profile is different from other antidepressants and includes convulsions and serious allergic reactions. Doxazosin and other alpha-blockers (terazosin, Hytrin® and prazosin, Minipress®) should not be used as first-line drugs in the management of elevated blood pressure.

PubMed Disclaimer

References

    1. Nolan JJ, Jones NP, Patwardhan R and Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet. Med. 2000;17: 287–294. - PubMed
    1. Raskin P, Rappaport EB, Cole STet al. . Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000;43:278–284. - PubMed
    1. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. A randomized controlled trial. JAMA, 2000;283:1695–1702. - PubMed
    1. Al-Saman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case Report. Ann Intern Med 2000; 132(2):121–4. - PubMed
    1. Public Citizen Health Research Group. Liver toxicity reported with the new diabetes drug rosiglitazone (Avandia). Worst Pills Best Pills News.2000;6(4):25–26, 29.

LinkOut - more resources